Ito S, Fujita T, Tamura N
Department of Immunology, University of Tsukuba, Ibaraki-ken, Japan.
J Immunol Methods. 1987 Dec 4;105(1):145-50. doi: 10.1016/0022-1759(87)90425-x.
We developed a quantitative enzyme-linked immunosorbent assay (ELISA) for the detection of C4b.C4-bp complex by incubating the sample on anti-C4-bp-coated plate and then developing with HRP-labeled anti-C4. The amount of C4b.C4-bp complex, generated in vivo by the interaction of purified C4b with C4-bp or normal human serum with aggregated human IgG, was measured by the ELISA. The complex, however, rapidly decreased in serum by the action of factor I. Six out of the 100 plasma samples from patients with various diseases were found positive in the ELISA. One plasma sample from a patient with SLE showed high level of C4b.C4-bp complex with decreased levels of factor I, C4, C4-bp and CH50. These results suggest that the detection of C4b.C4-bp complex is useful for monitoring the diseases in which the classical pathway activation is expected.
我们开发了一种定量酶联免疫吸附测定（ELISA）法，用于检测C4b.C4 - bp复合物。方法是将样品在包被有抗C4 - bp的平板上孵育，然后用辣根过氧化物酶（HRP）标记的抗C4进行显色。通过该ELISA法测定纯化的C4b与C4 - bp相互作用或正常人血清与聚集的人IgG在体内产生的C4b.C4 - bp复合物的量。然而，该复合物在血清中会因I因子的作用而迅速减少。在来自各种疾病患者的100份血浆样本中，有6份在ELISA检测中呈阳性。一份来自系统性红斑狼疮（SLE）患者的血浆样本显示C4b.C4 - bp复合物水平较高，而I因子、C4、C4 - bp和CH50水平降低。这些结果表明，检测C4b.C4 - bp复合物对于监测预期经典途径激活的疾病是有用的。
